Retatrutide vs Semaglutide: Triple Agonist vs Single GLP-1

Two compounds come up constantly for Canadian researchers working with GLP-1 peptides: Semaglutide, the molecule that founded the category, and Retatrutide, the newest and most mechanistically complete compound in it. This guide explains exactly how they differ and what each is suited to.

The core difference: one receptor vs three

That single line is most of the story. Semaglutide activates one receptor. Retatrutide activates three.

Semaglutide works purely through the GLP-1 pathway — appetite regulation, gastric emptying, and insulin response. Retatrutide retains all of that and adds two further mechanisms:

• GIP activation — supports insulin sensitivity and energy balance
• Glucagon receptor activation — increases energy expenditure and promotes fat mobilisation, a mechanism Semaglutide does not have at all

Depth of evidence vs breadth of mechanism

Semaglutide's single-pathway approach is the most extensively validated in the entire class. It has years of clinical data behind it and remains the benchmark every newer agonist is measured against. Retatrutide's triple mechanism is newer, with early-phase trials showing more pronounced metabolic effects, but a considerably shorter research history.

Neither is universally "better." Semaglutide offers depth of evidence and a well-characterised profile; Retatrutide offers the broadest mechanistic coverage currently available. The right compound depends entirely on the research question being asked.

Where Tirzepatide sits

Between the two. Tirzepatide is a dual GLP-1/GIP agonist — it adds the GIP pathway to Semaglutide's GLP-1 activity without the glucagon component that distinguishes Retatrutide. Researchers often use it as the intermediate comparator. Our Tirzepatide vs Semaglutide guide covers that pairing in detail.

Sourcing both in Canada

Both are available from Vancouver Island Peptides as domestic research compounds — synthesized at our Vancouver, BC lab partner, HPLC-verified to >99% purity, and shipped Canada-wide in discreet packaging. Unlike imported peptides, ours never cross a border, so there is no seizure risk and no cold-chain uncertainty.